Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Daiichi Sankyo's Welchol to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, sulfonylureas or insulin, either alone or in combination with other antidiabetic agents.
Subscribe to our email newsletter
Welchol (colesevelam HCl) is now claimed to be the first and only medication approved to reduce both glucose levels (colesevelam HCl) and low density lipoprotein cholesterol levels.
Joseph Pieroni, president and CEO of Daiichi Sankyo, said: “This approval represents an important milestone for our growing US organization and underscores our continued commitment to combating cardiovascular and metabolic diseases.”